Business Review for the Nine Months Ended September 30, 2013

• Sales: 2013 objective confirmed
  
  • Very good third quarter with sales up 7.4%* (5.7%* excluding R&D-related revenue)
  • Robust organic growth of 3.9% over the first nine months (3.3% excluding R&D-related revenue)
  • Sharp acceleration in North America
• Acquisition of BioFire, a U.S-based company specialized in molecular biology
• Successful placement of inaugural 7-year bond issue, in an amount of €300m

* At constant exchange rates and scope of consolidation

Marcy l'Etoile, France - October 23, 2013 - bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2013.

Sales for the first nine months of 2013 amounted to €1,144 million, representing a 3.9% year-on-year increase at constant exchange rates and scope of consolidation. The nine-month figure includes €6 million in R&D-related revenue, following retroactive billing. Excluding this non-recurring revenue, organic growth would have come to 3.3%.

Third-quarter sales totaled €390 million, up 7.4% from the year-earlier period (or 5.7% excluding R&D-related revenue).

“Over the third quarter, bioMérieux sales growth accelerated to 7.4%, lifting nine-month sales growth
to 3.3%, or 3.9% including non-recurring R&D-related revenue," said Jean-Luc Belingard, Chairman and Chief Executive Officer. “We pursued the launch of our VIDAS® 3 immunoassay platform, which is now available in 15 countries, and marketed a number of innovative new reagents, including a VIDAS® test for measuring vitamin D levels. Thanks to this good performance, we can confirm our organic growth objective for 2013 despite the high basis of comparison in the fourth quarter. During the period, we also entered into an agreement to acquire BioFire Diagnostics, Inc., a privately held U.S.-based company that markets a unique proprietary molecular biology solution for diagnosing infectious diseases, and successfully carried out our first bond issue, in an amount of €300 million. Backed by these advances, we are focused more than ever on executing our strategy."